» Articles » PMID: 37736748

Oral Squamous Cell Carcinomas: State of the Field and Emerging Directions

Overview
Journal Int J Oral Sci
Date 2023 Sep 22
PMID 37736748
Authors
Affiliations
Soon will be listed here.
Abstract

Oral squamous cell carcinoma (OSCC) develops on the mucosal epithelium of the oral cavity. It accounts for approximately 90% of oral malignancies and impairs appearance, pronunciation, swallowing, and flavor perception. In 2020, 377,713 OSCC cases were reported globally. According to the Global Cancer Observatory (GCO), the incidence of OSCC will rise by approximately 40% by 2040, accompanied by a growth in mortality. Persistent exposure to various risk factors, including tobacco, alcohol, betel quid (BQ), and human papillomavirus (HPV), will lead to the development of oral potentially malignant disorders (OPMDs), which are oral mucosal lesions with an increased risk of developing into OSCC. Complex and multifactorial, the oncogenesis process involves genetic alteration, epigenetic modification, and a dysregulated tumor microenvironment. Although various therapeutic interventions, such as chemotherapy, radiation, immunotherapy, and nanomedicine, have been proposed to prevent or treat OSCC and OPMDs, understanding the mechanism of malignancies will facilitate the identification of therapeutic and prognostic factors, thereby improving the efficacy of treatment for OSCC patients. This review summarizes the mechanisms involved in OSCC. Moreover, the current therapeutic interventions and prognostic methods for OSCC and OPMDs are discussed to facilitate comprehension and provide several prospective outlooks for the fields.

Citing Articles

A Truncated Mutation of TP53 Promotes Chemoresistance in Tongue Squamous Cell Carcinoma.

Du X, Zheng J, Lu X, Zhang Y Int J Mol Sci. 2025; 26(5).

PMID: 40076972 PMC: 11900931. DOI: 10.3390/ijms26052353.


Phytochemical analysis, antioxidant activity, and cytotoxic effects of Caulerpa lentillifera extracts inducing cell apoptosis and sub-G/G0-G1 cell cycle arrest in KON oral cancer cells.

Manmuan S, Sirirak T, Tubtimsri S, Petchsomrit A, Chuenbarn T BMC Complement Med Ther. 2025; 25(1):101.

PMID: 40069755 PMC: 11899751. DOI: 10.1186/s12906-025-04835-9.


The tumor coagulome as a potential biological determinant of postsurgical recurrence of oral squamous cell carcinoma.

Saidak Z, Galmiche A Front Oral Health. 2025; 6:1554739.

PMID: 40065838 PMC: 11891189. DOI: 10.3389/froh.2025.1554739.


Proteogenomic characterisation of primary oral cancer unveils extracellular matrix remodelling and immunosuppressive microenvironment linked to lymph node metastasis.

Liu Y, Yang Z, Pu J, Zhong J, Khoo U, Su Y Clin Transl Med. 2025; 15(3):e70261.

PMID: 40038875 PMC: 11879901. DOI: 10.1002/ctm2.70261.


The role of molecular biomarkers in the diagnosis, prognosis, and treatment stratification of oral squamous cell carcinoma: A comprehensive review.

Ravindran S, Ranganathan S, R K, J N, A S, Kannan S J Liq Biopsy. 2025; 7:100285.

PMID: 40027232 PMC: 11863969. DOI: 10.1016/j.jlb.2025.100285.


References
1.
Chai A, Lim K, Cheong S . Translational genomics and recent advances in oral squamous cell carcinoma. Semin Cancer Biol. 2019; 61:71-83. DOI: 10.1016/j.semcancer.2019.09.011. View

2.
Wang F, Zhang H, Xue Y, Wen J, Zhou J, Yang X . A systematic investigation of the association between HPV and the clinicopathological parameters and prognosis of oral and oropharyngeal squamous cell carcinomas. Cancer Med. 2017; 6(5):910-917. PMC: 5430083. DOI: 10.1002/cam4.1045. View

3.
Armstrong W, Kennedy A, Wan X, Atiba J, McLaren C, Meyskens Jr F . Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia. Cancer Epidemiol Biomarkers Prev. 2000; 9(1):43-7. View

4.
Rizzetto L, De Filippo C, Cavalieri D . Richness and diversity of mammalian fungal communities shape innate and adaptive immunity in health and disease. Eur J Immunol. 2014; 44(11):3166-81. DOI: 10.1002/eji.201344403. View

5.
Rayess H, Wang M, Srivatsan E . Cellular senescence and tumor suppressor gene p16. Int J Cancer. 2011; 130(8):1715-25. PMC: 3288293. DOI: 10.1002/ijc.27316. View